PrimeRFP SCOUT · Federal Contract Recompete Brief

80ARC022CA007Modeling anthracycline-triggered vascular — Brigham & Womens Hospital Inc

Brigham & Womens Hospital Inc holds $20.7M across 79 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards in the incumbent pipeline. Competition previously drew 9 offers. Set-aside status: Unrestricted. PoP ended Sep 26, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Nasa Ames Research Center
Awarding office
Brigham & Womens Hospital Inc
Recipient
Sep 26, 2026
PoP end
$2M
Obligated
$2M
Potential
541715
NAICS
AR11
PSC
Unrestricted
Set-aside
9 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Unrestricted
Contract number80ARC022CA007
AgencyNasa Ames Research Center
Awarding officeNasa Ames Research Center
Awarding agencyNational Aeronautics and Space Administration (NASA)
Funding agencyNational Aeronautics and Space Administration (NASA)
IncumbentBrigham & Womens Hospital Inc
CAGE0W3J1
UEIQN6MS4VN7BD1
NAICS541715
PSCAR11
Place of performanceBOSTON MA
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
Related solicitationNNH21ZDA015N
PoP startSep 27, 2022
PoP end (current)Sep 26, 2026
Obligated$2M
Current value$2M
Potential value$2M

MODELING ANTHRACYCLINE-TRIGGERED VASCULAR DYSFUNCTION is a federal Unrestricted award for Nasa Ames Research Center held by Brigham & Womens Hospital Inc. Estimated value $2M ($2M obligated). Current period of performance ends Sep 26, 2026. Last award drew 9 bidders. Place of performance: BOSTON MA. Related solicitation NNH21ZDA015N.

MODELING ANTHRACYCLINE-TRIGGERED VASCULAR DYSFUNCTION

Recompete timing

Public
● Past PoP end (4 days ago)

Current PoP ended Sep 26, 2026 (4 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Bonuses end Sept 30

Want the durability read on 80ARC022CA007? One Pursuit Analysis, $500, inside 48 business hours.

  • 48 business hours
  • $500
  • Credits toward the Pack
Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Brigham & Womens Hospital Inc — $20.7M obligated across 79 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($20.7M) · all agencies
Department of Veterans Affairs (VA)$13.0M · 63%Department of Health and Human Services (HHS)$6.9M · 33%National Aeronautics and Space Administration (NASA)$1.5M · 7%Department of Justice (DOJ)$14K · 0%
Open full company profile →

Related awards

Same incumbent
75F40122C00154
DESIGN A TWO-STAGE PROCESS FOR USING RWE TO SUPPORT LABELING EXPANSIONS FOR EFFECTIVENESS …
$2.7M
Sep 27, 2026
75N95021P00564
NANOSIMS ANALYSIS OF MITOCHONDRIAL METABOLISM IN MOUSE MODELS OF NEURODEGENERATION. ESTIMA…
$195K
Sep 26, 2026
36C24E25N0234
BIOINFORMATICS RESEARCH SUPPORT
$559K
Sep 13, 2026
36C24E25N0231
BIOINFORMATICS RESEARCH SUPPORT - DIV OF AGING
$542K
Sep 13, 2026
36C24E25N0235
BIOINFORMATICS RESEARCH SUPPORT
$399K
Sep 13, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract 80ARC022CA007?

80ARC022CA007 (Modeling anthracycline-triggered vascular) is a Nasa Ames Research Center award with a potential value of $2M, currently held by Brigham & Womens Hospital Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 80ARC022CA007?

Nasa Ames Research Center awarded 80ARC022CA007 to Brigham & Womens Hospital Inc (potential $2M).

Who is the incumbent on 80ARC022CA007?

Brigham & Womens Hospital Inc is the incumbent with $20.7M across 79 related awards in SCOUT’s public footprint. The current period of performance ends Sep 26, 2026.

When does Brigham & Womens Hospital Inc’s 80ARC022CA007 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 26, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 80ARC022CA007? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/80ARC022CA007